A retrospective study of a mandatory nonmedical switch in Canada found no significant differences in rates of treatment persistence, loss of response, or adverse events in patients with inflammatory ...

"These findings offer a way to identify IBD-SpA patients who are likely to respond to sulfasalazine therapy and also suggest new therapeutic approaches," said study senior author Dr. Randy Longman, ...

Although several treatment options exist in the management of Crohn's disease, a patient-centered approach is integral amid ...

Reddit stock is pushing past a cup-with-handle buy point as the social media player's third-quarter earnings report date ...

Difficult-to-treat IBD is prevalent among approximately a quarter of individuals with IBD in a tertiary care setting.

The mortality rate in IBD, ranging from 1999 to 2020, remained stable until 2018 when rates began to increase until 2020.

A lthough some health conditions are spoken about with more nuance and understanding than in the past, inflammatory bowel ...

Covenant Capital founder Nate Harris explains why he left Merrill and opted for the independent broker/dealer model, which he ...

AbbVie's Skyrizi and Rinvoq are rapidly growing, offsetting Humira's revenue decline. Read why ABBV presents a strong ...

Comorbidities and the type of surgical procedure, as opposed to race alone, are significantly more associated with postoperative complications in IBD.

Shattuck Labs Inc. has announced a strategic shift to focus on SL-325, a death receptor 3 (DR3) antagonist antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory ...

An anti-TL1A monoclonal antibody called tulisokibart may help people with moderate to severe ulcerative colitis achieve ...